復星醫藥(02196.HK)創新腫瘤免疫療法FXB0871中國I期臨床試驗完成首例參與者給藥

阿斯達克財經

05/29

復星醫藥(02196.HK) 宣佈，創新腫瘤免疫療法FXB0871在中國境內(不包括港澳台地區)的I期臨床試驗已完成首例參與者給藥。FXB0871是復星醫藥與以色列Teva(TEVA.US) 合作開發的PD-1靶向型減弱IL-2融合蛋白的免疫療法(ATTENUKINE)。這標誌着該臨床試驗藥物在中國臨床開發進程中取得的一個重要里程碑，也為後續差異化免疫腫瘤聯合治療的探索奠定了關鍵基礎。...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2639626872"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2639626872\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2639626872?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20170911103105061_s.JPG","is_english":false,"pubTime":"2026-05-29 17:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639626872","market":"sh","top_or_hot":-1,"title":"復星醫藥(02196.HK)創新腫瘤免疫療法FXB0871中國I期臨床試驗完成首例參與者給藥","media":"阿斯達克財經","content":"<div>\n<p>復星醫藥(02196.HK) 宣佈，創新腫瘤免疫療法FXB0871在中國境內(不包括港澳台地區)的I期臨床試驗已完成首例參與者給藥。FXB0871是復星醫藥與以色列Teva(TEVA.US)  合作開發的PD-1靶向型減弱IL-2融合蛋白的免疫療法(ATTENUKINE)。這標誌着該臨床試驗藥物在中國臨床開發進程中取得的一個重要里程碑，也為後續差異化免疫腫瘤聯合治療的探索奠定了關鍵基礎。...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1526757/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>復星醫藥(02196.HK)創新腫瘤免疫療法FXB0871中國I期臨床試驗完成首例參與者給藥</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n復星醫藥(02196.HK)創新腫瘤免疫療法FXB0871中國I期臨床試驗完成首例參與者給藥\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2026-05-29 17:43</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>復星醫藥(02196.HK) 宣佈，創新腫瘤免疫療法FXB0871在中國境內(不包括港澳台地區)的I期臨床試驗已完成首例參與者給藥。FXB0871是復星醫藥與以色列Teva(TEVA.US)  合作開發的PD-1靶向型減弱IL-2融合蛋白的免疫療法(ATTENUKINE)。這標誌着該臨床試驗藥物在中國臨床開發進程中取得的一個重要里程碑，也為後續差異化免疫腫瘤聯合治療的探索奠定了關鍵基礎。...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1526757/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1526757/latest-news/AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"醫美概念股","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1526757/latest-news/AAFN","article_id":"2639626872","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20170911103105061_s.JPG"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1526757/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2639626872","pubTimestamp":1780047780,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"復星醫藥宣佈，創新腫瘤免疫療法FXB0871在中國境內的I期臨床試驗已完成首例參與者給藥。FXB0871是一款PD-1靶向型減弱IL-2融合蛋白免疫療法，為一款全球前沿的創新藥物。FXB0871旨在將減弱的IL-2選擇性遞送至PD-1陽性的T細胞，從而增強T細胞抗腫瘤活性，同時儘可能減少非靶向的系統性毒性。迄今為止，全球範圍內尚無基於IL-2並可選擇性靶向遞送至腫瘤反應性T細胞的藥品獲批上市。目前，TEV-56278/FXB0871的國際多中心I期臨床研究正在美國及加拿大開展。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK1593":"医美概念股","BK0175":"白马股","BK0196":"行业龙头","BK1515":"抗疫概念","BK0012":"证金概念","BK0187":"一线龙头","BK0060":"抗癌","02196":"复星医药","BK1191":"制药","BK0188":"融资融券","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK0096":"民营医院"},"translate_title":"Fosun Pharma (02196.HK) Phase I clinical trial of innovative tumor immunotherapy FXB0871 in China completes first participant dosing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1.5,"02196":1.5},"content_text":"復星醫藥(02196.HK) 宣佈，創新腫瘤免疫療法FXB0871在中國境內(不包括港澳台地區)的I期臨床試驗已完成首例參與者給藥。FXB0871是復星醫藥與以色列Teva(TEVA.US)  合作開發的PD-1靶向型減弱IL-2融合蛋白的免疫療法(ATTENUKINE)。這標誌着該臨床試驗藥物在中國臨床開發進程中取得的一個重要里程碑，也為後續差異化免疫腫瘤聯合治療的探索奠定了關鍵基礎。FXB0871(復星醫藥權益範圍外藥物名稱為TEV-56278)是一款PD-1靶向型減弱IL-2融合蛋白免疫療法(ATTENUKINETM)，為一款全球前沿的創新藥物。FXB0871旨在將減弱的IL-2選擇性遞送至PD-1陽性的T細胞，從而增強T細胞抗腫瘤活性，同時儘可能減少非靶向的系統性毒性。臨床前研究數據顯示，該藥物可實現腫瘤消退、增強T細胞浸潤並形成持久的免疫記憶。迄今為止，全球範圍內尚無基於IL-2並可選擇性靶向遞送至腫瘤反應性T細胞的藥品獲批上市。根據雙方此前達成的協議，復星醫藥擁有該產品在中國及約定的東南亞國家的獨家開發、生產和商業化權利，雙方將共享臨床數據，共同加速這一創新療法的研發進展。目前，TEV-56278/FXB0871的國際多中心I期臨床研究正在美國及加拿大開展。(da/a)(港股報價延遲最少十五分鐘。沽空資料截至 2026-05-29 16:25。) (美股為即時串流報價； OTC市場股票除外，資料延遲最少15分鐘。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}